Atea Pharmaceuticals
Clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious viral infections, including hepatitis C, COVID-19, and other viral diseases.
Notes
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious viral infections. The company has developed nucleotide prodrug candidates that target viral RNA polymerase, with applications in hepatitis C, COVID-19, dengue, and other viral diseases.
Atea's lead program bemnifosbuvir (AT-527) is an oral antiviral developed for the treatment of COVID-19 and hepatitis C. The company has explored partnerships with major pharmaceutical companies for development and commercialization of its antiviral candidates.
The company is publicly traded on NASDAQ under the ticker symbol AVIR. Atea is backed by Bain Capital Life Sciences and other leading healthcare investors.
Team
- Jean-Pierre Sommadossi, Ph.D. - Founder, President & Chief Executive Officer
- LinkedIn: linkedin.com/in/jean-pierre-sommadossi
- Andrea Corcoran - Chief Financial Officer & General Counsel
- Janet Hammond, M.D. - Chief Medical Officer
Additional Research Findings
- NASDAQ listed company (AVIR)
- Lead candidate bemnifosbuvir (AT-527)
- Focus on oral antivirals for hepatitis C, COVID-19, dengue
- Nucleotide prodrug technology platform
- Backed by Bain Capital Life Sciences
- Boston, Massachusetts headquarters
- Founder has extensive antiviral drug development experience
- Founded 2012